Multi-stakeholder consensus on a target product profile for an HIV cure
| Autor: | Devi SenGupta, Pottage John C, Moses Supercharger Nsubuga, Thumbi Ndung'u, Timothy Attoye, Mitchell Warren, David Ripin, Rowena Johnston, Karine Dubé, Brian P. Doehle, Izukanji Sikazwe, Mark Dybul, Joseph M. McCune, Sharon R Lewin, Rosanne Lamplough, Steven G. Deeks, Cathy Bansbach, James F. Rooney, Adam Jiang, Gary J Nabel |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Consensus Epidemiology Immunology HIV Infections Review 03 medical and health sciences 0302 clinical medicine Public health surveillance Acquired immunodeficiency syndrome (AIDS) Antiretroviral Therapy Highly Active Virology Intervention (counseling) medicine Humans Combined Modality Therapy Public Health Surveillance Medical physics 030212 general & internal medicine Product (category theory) Disease management (health) Expert Testimony computer.programming_language business.industry Disease Management HIV medicine.disease 030112 virology Infectious Diseases Drug development business computer Delphi |
| Zdroj: | Lancet HIV The Lancet. HIV |
| ISSN: | 2352-3018 |
| Popis: | Summary Developing a cure for HIV is a global priority. Target product profiles are a tool commonly used throughout the drug development process to align interested parties around a clear set of goals or requirements for a potential product. Three distinct therapeutic modalities (combination therapies, ex-vivo gene therapy, and in-vivo gene therapy) for a target product profile for an HIV cure were identified. Using a process of expert face-to-face consultation and an online Delphi consultation, we found a high degree of agreement regarding the criteria for the optimum target product profile. Although the minimum attributes for a cure were debated, the broad consensus was that an acceptable cure need not be as safe and effective as optimally delivered antiretroviral therapy. An intervention that successfully cured a reasonable fraction of adults would be sufficient to advance to the clinic. These target product profiles will require further discussion and ongoing revisions as the field matures. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|